DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
तुलना करने के लिए मीट्रिक्स | DBVT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधDBVTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.7x | −1.9x | −0.4x | |
PEG अनुपात | −0.83 | 0.32 | 0.00 | |
क़ीमत/बुक | 7.6x | 3.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 226.2x | 3.8x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 114.5% | 39.3% | 49.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.9% | 6.8% | अनलॉक करें |